EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Price, Timothy ^{[1
]}

Chawla, Sant ^{[2
]}

Falchook, Gerald ^{[3
]}

Prenen, Hans ^{[4
]}

Lugowska, Iwona ^{[5
]}

Subbiah, Vivek ^{[6
]}

Monzon, Jose ^{[7
]}

Ozawa, Yuichi ^{[8
]}

Arkenau, Tobias ^{[9
]}

Lima, Caio Rocha ^{[10
]}

Kuboki, Yasutoshi ^{[11
]}

Nishina, Tomohiro ^{[12
]}

Hui, Mun ^{[13
]}

Rasmussen, Erik ^{[14
]}

Wong, Hansen ^{[14
]}

Najmi, Saltanat ^{[14
]}

Sadraei, Nooshin ^{[14
]}

机构：

[1] Univ Adelaide, Queen Elizabeth Hosp Campus, CALHN, Woodville, SA, Australia

[2] Sarcoma Oncol Ctr, Santa Monica, CA USA

[3] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[4] Univ Hosp Antwerp, Antwerp, Belgium

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Texas MD Anderson Canc, Houston, TX USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Wakayama Med Univ Hosp, Wakayama, Japan

[9] Sarah Cannon Res Inst UK, London, England

[10] Wake Forest Baptist Hlth, Miami, FL USA

[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[13] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[14] Amgen Inc, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

403

引用

页码：A245 / A245

页数：1

共 50 条

[41] A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.
Kotasek, Dusan
Coward, Jermaine
de Souza, Paul L.
Underhill, Craig
Jin, Xiaoping
Li, Baiyong
Xia, Yu
Prawira, Amy
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Impact of body composition on outcomes from anti programmed death-1 (PD-1) treatment.
Young, Arissa
Quach, Henry T.
Davis, Elizabeth J.
Moslehi, Javid
Williams, Grant R.
Johnson, Douglas Buckner
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors
Liu, Jiajian
Zhou, Caicun
Li, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
Topalian, S. L.
Brahmer, J. R.
Hodi, F. S.
McDermott, D. F.
Smith, D. C.
Gettinger, S.
Taube, J. M.
Gupta, A.
Wigginton, J. M.
Sznol, M.
ANNALS OF ONCOLOGY, 2012, 23 : 157 - 157
[45] Long-term efficacy and safety of programmed death-1 (PD-1) antibody alone in relapsed/refractory human immunodeficiency virus-associated Hodgkin lymphoma
Wang, Chaoyu
Zhou, Fanlin
Zhang, Lingqian
Liu, Tingting
Nan, Yingyu
Liu, Yao
EJHAEM, 2022, 3 (03): : 924 - 926
[46] Phase 1 trial of JS']JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.
Yang, Jianliang
Yang, Sheng
Song, Haifeng
Han, Xiaohong
Han, Ying
Jiang, Shiyu
Yao, Jiarui
Zhang, Zhishang
Zhang, Shuxiang
Liu, Peng
Qin, Yan
Zhou, Shengyu
He, Xiaohui
Wang, Yan
Cui, Chengxu
Feng, Hui
Yao, Sheng
Sun, Yan
Shi, Yuankai
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Predictive markers for programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade therapy in patients with metastatic melanoma (MM).
Kim, Dae Won
Chakravarti, Nitin
Trinh, VanAnh
Perdon, Karen Mae
McIntyre, Susan E.
Prieto, Victor G.
Hwu, Wen-Jen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48] Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome
Kobayashi, M
Kawano, S
Hatachi, S
Kurimoto, C
Okazaki, T
Iwai, Y
Honjo, T
Tanaka, Y
Minato, N
Komori, T
Maeda, S
Kumagai, S
JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2156 - 2163
[49] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
Naito, Yoichi
Kuboki, Yasutoshi
Ikeda, Masafumi
Harano, Kenichi
Matsubara, Nobuaki
Toyoizumi, Shigeyuki
Mori, Yuko
Hori, Natsuki
Nagasawa, Takashi
Kogawa, Takahiro
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
[50] Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial
Awada, Ahmad
Gil, Thierry
Whenham, Nicolas
Van Hamme, Julie
Besse-Hammer, Tatiana
Brendel, Erich
Delesen, Heinz
Joosten, Miranda C.
Lathia, Chetan D.
Loembe, Bienvenu A.
Piccart-Ghebart, Martine
Hendlisz, Alain
JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1674 - 1684

← 1 2 3 4 5 →